PUBLICATION
Quinoline Compound KM11073 Enhances BMP-2-Dependent Osteogenic Differentiation of C2C12 Cells via Activation of p38 Signaling and Exhibits In Vivo Bone Forming Activity
- Authors
- Baek, S.H., Choi, S.W., Park, S.J., Lee, S.H., Chun, H.S., Kim, S.H.
- ID
- ZDB-PUB-150320-3
- Date
- 2015
- Source
- PLoS One 10: e0120150 (Journal)
- Registered Authors
- Keywords
- none
- MeSH Terms
-
- Alkaline Phosphatase/metabolism
- Animals
- Bone Morphogenetic Protein 2/genetics
- Bone Morphogenetic Protein 2/metabolism
- Bone Morphogenetic Protein 2/pharmacology*
- Bone Morphogenetic Protein 6/genetics
- Bone Morphogenetic Protein 6/metabolism
- Bone Morphogenetic Protein 7/genetics
- Bone Morphogenetic Protein 7/metabolism
- Cell Differentiation/drug effects*
- Cell Line
- Humans
- Mice
- Osteogenesis/drug effects*
- Osteopontin/genetics
- Osteopontin/metabolism
- Piperazines/chemistry
- Piperazines/pharmacology*
- Quinolines/chemistry
- Quinolines/pharmacology*
- RNA, Messenger/metabolism
- Recombinant Proteins/pharmacology
- Regenerative Medicine
- Signal Transduction/drug effects*
- Skull/pathology
- Smad Proteins/metabolism
- Transforming Growth Factor beta/pharmacology*
- Zebrafish/growth & development
- p38 Mitogen-Activated Protein Kinases/metabolism
- PubMed
- 25789987 Full text @ PLoS One
- CTD
- 25789987
Citation
Baek, S.H., Choi, S.W., Park, S.J., Lee, S.H., Chun, H.S., Kim, S.H. (2015) Quinoline Compound KM11073 Enhances BMP-2-Dependent Osteogenic Differentiation of C2C12 Cells via Activation of p38 Signaling and Exhibits In Vivo Bone Forming Activity. PLoS One. 10:e0120150.
Abstract
Recombinant human bone morphogenetic protein (rhBMP)-2 has been approved by the FDA for clinical application, but its use is limited due to high cost and a supra-physiological dose for therapeutic efficacy. Therefore, recent studies have focused on the generation of new therapeutic small molecules to induce bone formation or potentiate the osteogenic activity of BMP-2. Here, we show that [4-(7-chloroquinolin-4-yl) piperazino][1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl]methanone (KM11073) strongly enhances the BMP-2-stimulated induction of alkaline phosphatase (ALP), an early phase biomarker of osteoblast differentiation, in bi-potential mesenchymal progenitor C2C12 cells. The KM11073-mediated ALP induction was inhibited by the BMP antagonist noggin, suggesting that its osteogenic activity occurs via BMP signaling. In addition, a pharmacological inhibition study suggested the involvement of p38 activation in the osteogenic action of KM11073 accompanied by enhanced expression of BMP-2, -6, and -7 mRNA. Furthermore, the in vivo osteogenic activity of KM11073 was confirmed in zebrafish and mouse calvarial bone formation models, suggesting the possibility of its single use for bone formation. In conclusion, the combination of rhBMP-2 with osteogenic small molecules could reduce the use of expensive rhBMP-2, mitigating the undesirable side effects of its supra-physiological dose for therapeutic efficacy. Moreover, due to their inherent physical properties, small molecules could represent the next generation of regenerative medicine.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping